EUCTR2019-002106-52-GB进行中（未招募）1 期
CANnabidiol for Behavioural Symptoms in Alzheimer’s Disease - CANBiS-AD
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •(1) Age 55 and above from both genders;
- •(2) Living within the SLAM/South London region;
- •(3) Diagnosis of AD according to the criteria of National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA);
- •(4) Clinical Dementia Rating (CDR) score between 0.5-2;
- •(5) BPSD lasting for at least 2 weeks with total score on Neuropsychiatric Inventory (NPI) =4 and at least 1 item with moderate frequency or severity on one of the domains of anxiety, agitation, hallucinations or delusions;
- •(6) If treated with cholinesterase inhibitors (donepezil, rivastigmine or galantamine) and/or memantine, dosage must have been stable for at least 1 month; If ChEIs and/or memantine has been discontinued, they may enrol 1 month following discontinuation.
- •(7) Ability to participate in study evaluation and ingest oral medication.
- •(8) Reliable informant/caregiver.
- •(8) Written informed consent from participant or their legally authorised representative.
- •Eligibility criteria for caregivers:
- •(1) See the patient for an average of 6 hours per week
- •(2) Willing to attend all study visits with the participant and participate in weekly calls
- •(3) Able to answer questions about the participant’s behavioural and psychological symptoms, daily activities, quality of life, memory, health and any side effects that they may be experiencing from the study medication
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 5
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 35
排除标准
- •(1) Presence or history of other psychiatric or neurological disorders (e.g. psychotic disorders, schizophrenia, major depressive illness including suicidal ideation, stroke, epilepsy) or severe intercurrent physical illness that could interfere with the conduct of the study.
- •(2) Participants who answer yes on the C-SSRS Suicidal Ideation Item 4 or Item 5 (Active Suicidal Ideation with Some Intent to Act, Without Specific Plan, or Active Suicidal Ideation with Specific Plan and Intent) and whose most recent episode meeting the criteria for C-SSRS Item 4 or Item 5 occurred within the last 6 months, OR Participants who answer yes on any of the 5 C-SSRS Suicidal Behavior Items (actual attempt, interrupted attempt, aborted attempt, preparatory acts, or behavior) and whose most recent episode meeting the criteria for any of these 5 C-SSRS Suicidal Behavior iItems occurred within the last 2 years, OR Participants who, in the opinion of the investigator, present a serious risk of suicide.
- •(3) Changes in dosage of antidepressants within 4 weeks before randomization and during study, and changes in dosage antipsychotics or benzodiazepines within 2 weeks prior to randomization and during study.
- •(4) Use of co-medication that has a clinically relevant interaction with the CYP2C19 or CYP3A classes of liver enzymes will not be permitted from two weeks before inclusion until the end of the study. Examples of co-medication that will be not allowed will include CYP3A4 inhibitors (such as itraconazole, ketoconazole, posaconazole, fluconazole, erythromycin, clarithromycin, telithromycin, HIV protease inhibitors, nefazodone, telaprevir, boceprevir, imatinib, ticagrelor, voriconazole), CYP3A4 inducers (such as grapefruit juice, carbamazepine, efavirenz, nevirapin, etravirin) and CYP2C19 inhibitors (such as moclobemine, fluvoxamine, chloramphenicol, fluoxetine).
- •(5) If the patient has participated in other interventional clinical studies within 30 days of baseline.
- •(6) Female patients who are pregnant or lactating
- •(7) Female patients of childbearing potential* who are not willing to use a highly effective method of contraception** for the duration of the trial (from the date of consent until entire study duration, i.e., until the 4 weeks follow up visit post-treatment) to prevent pregnancy or abstain from heterosexual activity. *Females of childbearing potential are females who have experienced menarche and are not surgically sterilised (e.g. hysterectomy or bilateral salpingectomy) or postmenopausal (defined as at least 1 year since last regular menstrual period).
- •** Highly effective methods of birth control are those with a failure rate of < 1% per year when employed consistently and correctly, e.g. • combined (oestrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation: o oral o intravaginal o transdermal • progestogen-only hormonal contraception associated with inhibition of ovulation 1: o oral o injectable o implantable 2 • intrauterine device (IUD) • intrauterine hormone-releasing system ( IUS) • vasectomised partner
- •Sexual abstinence is considered to be highly effective method only if defined as refraining from heterosexual activity from the date of consent until entire study duration, i.e., until the 4 weeks follow up visit post-treatment. The reliability of this method should be evaluated in relation to the duration of the study and the preferred and usual lifestyle of the participant.
研究者
相似试验
尚未招募
不适用
To improve early recgonition and tailored treatment of behavioral changes in patients with Alzheimer's disease and Mild Cognitive Impairment visiting the memory clinicAlzheimer's disease, Mild Cognitive Impairment, dementiaDe ziekte van Alzheimer, Milde Cognitieve Stoornissen, dementieNL-OMON28628Erasmus Medical Center150
进行中（未招募）
2 期
se of Cannabidiol in the treatment of psychiatric symptoms of Vascular DementiaC10.228.140.380Vascular dementiaRBR-686kmpzFaculdade de Medicina de Ribeirão Preto- Universidade de São Paulo (FMRP-USP)
已完成
2 期
Use of a Cannabinoids as a Treatment Strategy for Alzheimer's DiseaseAlzheimer DiseaseNCT06570928Federal University of Latin American Integration72
终止
2 期
Cannabidiol: Treatment for brain changes and depression in early-stage dementiaEarly-stage dementiaNeurological - DementiasACTRN12621001364864niversity of Wollongong1
已完成
2 期
Safety and Efficacy of Nabilone in Alzheimer's DiseaseAlzheimer DiseaseAgitationWeight LossPainOxidative StressNCT02351882Sunnybrook Health Sciences Centre38